Researchers at the National Institutes of Health have launched a new clinical trial investigating an innovative combination approach for people with early-stage, operable non-small cell lung cancer (NSCLC). The study, known as AZA-AEGEAN, pairs an inhaled form of the epigenetic drug azacytidine with the already-approved neoadjuvant regimen of durvalumab and platinum-based chemotherapy, exploring whether this combined epigenetic-immunotherapy strategy can further improve outcomes before surgery.
NSCLC remains the most common form of lung cancer, and while surgery is the standard treatment for early-stage disease, tumors can sometimes return even after successful removal. Durvalumab plus chemotherapy given before surgery is already an FDA-approved option shown to help some patients, but researchers are now asking whether adding inhaled azacytidine could offer an additional benefit by targeting cancer cells directly in the lungs.
What makes this approach particularly promising is the delivery method: rather than delivering azacytidine intravenously, as it is used in other approved indications, the trial uses a nebulized, inhaled version similar to an asthma inhaler mist. This route is designed to concentrate the drug’s effects directly in lung tissue while limiting how much enters the bloodstream, potentially reducing systemic exposure while still working to sensitize tumor cells epigenetically before the immune-boosting and chemotherapy components take effect.
The trial is carefully structured to gather robust data, including pre- and post-treatment biopsies, imaging, and bronchial fluid collection, allowing researchers to closely study how the combination affects tumor tissue at a cellular level. Participants will undergo three treatment cycles before their planned surgery, followed by regular monitoring for up to three years afterward, an approach that should provide valuable long-term insight into how this regimen influences recurrence and recovery.
This type of research represents an encouraging step in the ongoing effort to refine and personalize treatment for early-stage lung cancer, potentially opening the door to more effective pre-surgical options that combine multiple therapeutic strategies. While it is still early days for this specific combination, trials like this help build the foundation for future advances in thoracic oncology care. This article is for informational purposes only and is not intended as medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Leave a Reply